Viatris reported 2025 revenue of $14.30 billion and Q1 2026 revenue of $3.52 billion. The thesis depends on durable generic-drug cash flow, portfolio pruning, debt reduction, regulatory execution and proof that recent losses are not masking a weakening franchise.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-20 · Issuer identity, ticker, exchange and CIKSEC APISEC submissions APIRetrieved 2026-05-20 · Filing chronology and company identitySEC XBRL APISEC companyfacts APIRetrieved 2026-05-20 · Financial statement cross-checksAnnual report2025 Form 10-K filed 2026-02-262026 · Annual business, risk and financial baselineQuarterly reportQ1 2026 Form 10-Q filed 2026-05-072026 · Latest interim financial baselineCurrent reportForm 8-K filed 2026-05-152026 · Recent filing chronologyProxy statementDEF 14A filed 2026-04-022026 · Governance and incentive context